Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (T H 2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from T H 2 cells, is a potent pruritogenic cytokine, and its sys- First-line treatments of AD include the application of emollients for dry skin, topical steroids, and tacrolimus for skin inflammation, followed by second-line adjunct therapies such as systemic cyclosporine, short-term oral steroids, and ultraviolet radiation.
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Itch is a specialized perception of the skin, leading to a scratching behavior that is often observed in terrestrial mammals. Itch-induced scratching appears to exacerbate skin lesions in clinical and experimental dermatitis. 2, 3 Itching and scratching cause sleep loss and severely disturb the quality of life of affected individuals. 4, 5 First-line treatments of AD include the application of emollients for dry skin, topical steroids, and tacrolimus for skin inflammation, followed by second-line adjunct therapies such as systemic cyclosporine, short-term oral steroids, and ultraviolet radiation. 1, 2 Although many reports confirm the antipruritic effects of conventional treatments, 6 the satisfaction and adherence to treatments are typically very low in patients with AD. 7 Development of new antipruritic agents is in demand.
Itch is mediated by unmyelinated C-fibers and thinly myelinated
Ad fibers originated from cell bodies in the dorsal root ganglion (DRG). 4, 8, 9 Diverse endogenous and exogenous pruritogens such as histamine, 5-hydroxytryptamine, proteases, substance P, and chloroquine are known to induce itch sensation (Table 1) . [8] [9] [10] Each pruritogen mediates itch via specific receptor (Table 1) . 8, 9 Itch-specific peripheral neurons are positive for Mas-related G-protein-coupled receptor A3 (MargprA3) because genetic ablation of MargprA3-positive neurons attenuated scratch responses to chloroquine and histamine without affecting pain behaviors. 11 The neuronal mechanism of itch sensation is not fully understood; however, the histaminergic itch pathway uses transient receptor potential cation channel vanilloid subtype 1 (Trpv1) as a direct downstream target. In nonhistaminergic itch, some pruritogens (eg, chloroquine) use transient receptor potential cation channel ankyrin subtype 1 (Trpa1). 8, 9, 12 Besides chemical mediators, increasing research attention is being paid to interleukin-31 (IL-31) and its receptor as an itch mediator since discovering the pruritogenic action of IL-31 in mice in 2004. 13 Indeed, systemic and local administration of IL-31 induces scratching behavior in rodents, dogs, and cynomolgus monkeys. [13] [14] [15] [16] [17] [18] [19] Prick testing with an IL-31 solution triggers the itch sensation in humans. 20 Recent clinical studies have demonstrated that blockade of IL-31 signals by a specific antibody alleviates pruritus in patients with AD. 21, 22 In this review, we summarize recent reports on IL-31 and its receptor with special reference to atopic itch.
| STRUCTURE AND EXPRESSION OF TH E IL-31 /IL-31R SYSTEM
Interleukin-31 is a four-helix bundle cytokine belonging to the IL-6 cytokine family. 23 IL-31 mRNA is preferentially, but not exclusively, expressed by CD4+ T helper 2 (T H 2) cells after activation and by cutaneous lymphocyte-associated antigen-positive skin-homing CD45RO+ (memory) T cells. 13, 24, 25 42 In contrast, anemia or thrombocytopenia is seen in the Osmr-deficient mice. 43 However, regulatory role of IL-31/IL-31R system in T H 2 response remains controversial. In the Il31ra-deficient mice, T H 2-dependent pulmonary granulomatous reaction induced by Schistosoma mansoni egg injection is significantly augmented in lung, suggesting an inhibitory role of IL-31/IL-31R in T H 2 immune response. 42 Intraperitoneal injection of Cryj2 pollen antigen in Il31ra-deficient mice also shows a stronger T H 2 response compared to wild-type mice. 44 In contrast, intranasal application of Cryj2 significantly inhibits the T H 2 response in the Il31ra-deficient mice. 44 Furthermore, the T H 2 immune response induced by subcutaneous injection of ovalbumin and alum is not altered either in Il31ra deficiency or by anti-IL-31 neutralization antibody. 45 These results suggest that the IL-31/IL-31R signal may affect the T H 2 immune response positively or negatively depending on the route of antigen administration. 
| ESSENTIAL ROLE OF TRANSCRIPTION FACTOR EPAS1 IN IL-31 PRODUCTION
Interleukin-4 induces the gene expression and protein release of IL-31 from human T H 2 cell subset. [31] [32] [33] Staphylococcal enterotoxin B is a potent inducer of mRNA and protein levels of IL-31 from peripheral blood mononuclear cells of healthy and AD subjects. 34, 35 However, the upstream signaling pathway leading to IL-31 production has remained unknown.
Homozygous and compound heterozygous mutations in DOCK8
cause a combined immunodeficiency with AD-like skin lesions and elevated serum IgE levels. 53 In human CD4+ T cells from healthy controls, knockdown of the DOCK8 gene markedly increases IL-31 gene expression, indicating that DOCK8 acts as a negative regulator for IL-31 induction. 54 More importantly, the induction of the IL-31 gene expression is inhibited when EPAS1 gene expression is knocked down in CD4+ T cells from patients with AD ( Figure 1 Crosstalk between TLRs and DOCK8 is also potentially important for IL-31 gene expression in T H 2 cells.
In mice, the binding of transcription factors Epas1 and Sp1 to the promoter region of the Il31 gene is indispensable for IL-31 production. 54 The interaction of Epas1 and another transcription factor Sp1 has been reported in hypoxic condition. 58, 59 In the unstimulated condition, Epas1 mainly resides in the cytoplasm in association with Mst1, a serine/threonine kinase ( Figure 1) . Notably, knockdown of
Mst1 augments the nuclear translocation of Epas1 and markedly induces Il31 gene expression in CD4+ T cells. 54 Furthermore, Dock8
binds to Mst1 and prevents the nuclear translocation of Epas1 and subsequent IL-31 production ( Figure 1 ). 54 These human and murine results highlight EPAS1 as a potential therapeutic target for regulating the production of IL-31.
| ITCH AND NEURONAL SPREADING THROUGH THE IL-31/IL-31R SYSTEM
The human IL-31 sequence is more than 80% identical to rhesus, cynomolgus, and marmoset monkeys, but it is only 54% identical to dog and only 30%-31% identical to rat and mouse sequences.
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Steady state Hawro et al. 20 used an IL-31 prick test to challenge patients with AD and healthy controls, showing that IL-31 evokes a late-onset itch response with lower intensity than that evoked by a histamine challenge in AD and healthy volunteers. 20 They speculated that IL-31 may exert its pruritic effect indirectly via keratinocytes and secondary mediators, rather than through direct activation of its receptors on cutaneous nerves. 20 However, it should be mentioned that the amount of IL-31 by skin prick administration may be too low to induce significant itch sensation.
The expression of IL-31RA is identified in cutaneous neurons
and DRG in mice, cynomolgus monkeys, and humans. 8 In addition to AD, the itch-inducing effects of IL-31/IL-31R are consistent with data showing that the expression of IL-31 and IL-31R is elevated in prurigo nodularis, which exhibits a chronic and intolerable itch sensation. 8, 24, 34, 54 In addition, epidermal IL-31 levels correlate to itch severity in cutaneous T-cell lymphoma. 65 In the lesional skin of AD, the density of cutaneous neuronal networks is increased with hyperinnervation into the epidermis and thickened dermal nerve fibers. 4, 9, 66 The Il31 transgenic mice or mice supplemented with an isoosmotic pump dispensing IL-31 develop AD-like skin lesions with scratching. 61 The lesional skin of these mice is hyperinnervated. 61 In accordance, IL-31 promotes nerve fiber elongation and branching of murine small-diameter DRG neurons, which is abrogated in DRG neurons from Il31ra-deficient mice. 61 Moreover, the IL-31-induced nerve fiber elongation is independent of Trpv1 but dependent on Stat3 activation (Figure 1 ). 61 Interestingly, Stat3 also plays a pivotal role in the formation of reactive astrogliosis in the spinal cord, which causes chronic itch. 67 These studies indicate that IL-31 binds to IL-31RA on the sensory nerve and evokes itch sensation via TRPV1 and TRPA1 ion channel activation. IL-31 also promotes the elongation and branching of IL-31RA+ sensory nerve fibers, and thereby, it may self-aggravate itch sensation.
| SUCCESSFUL ITCH CONTROL IN A CLINICAL TRIAL FOR ATOPIC DERMATITIS BY BLOCKING IL-31/IL-31R SIGNALING
Itch is a cardinal symptom of AD. 1 The expression of IL-31 is augmented in lesional skin and peripheral blood lymphocytes in AD compared with healthy controls. 8, 24, 34, 54, 68 IL-31 is significantly overexpressed in pruritic atopic compared with nonpruritic psoriatic skin inflammation. 34 In addition, the serum levels of IL-31 are significantly increased in AD compared to healthy controls and are correlated with the severity of pediatric and adult AD. 69, 70 The levels of IL-31RA expressed on keratinocytes of lesional skin in AD are consistently higher than the levels observed in those of normal skin in healthy control subjects. 24 The expression of IL-31RA is also significantly increased in the lesional skin of psoriasis but to a lesser extent than in AD. 8 Notably, the expression levels of OSMR are comparable among control, psoriasis, and AD skin samples. 8 These results underscore the importance of IL-31RA than OSMR in the pathogenesis of AD. 8, 24 A randomized, double-blind, placebo-controlled phase I/Ib clinical trial of nemolizumab (a humanized anti-human IL-31RA antibody) 19 was conducted in 56 Japanese and 24 white healthy volunteers and in 36 Japanese patients with AD. 21 The primary outcomes were safety and tolerability, and the exploratory analysis was efficacy. The patients with AD were not allowed to use concomitant drugs other than topical hydrocortisone butyrate and moisturizers. An interindividual dose-escalation study method was performed by a single subcutaneous injection at doses of 0.003, 0.01, 0.03, 0.1, 0.3, 1.0, or 3 mg/kg. All adverse events were mild or moderate. No dose-dependent increase in the incidence of adverse events occurred in any study part. 21 The pruritus visual analogue scale (VAS) was markedly decreased at week 1 after administration (À24%, À24% and À33% in the 0.3, 1.0 and 3.0 mg/kg nemolizumab groups, respectively, vs.
À9% in the placebo group). The change in pruritus VAS score at week 4 from baseline was À50%, À44%, and À48% in the 0.3, 1.0, and 3.0 mg/kg nemolizumab groups, respectively, compared with À20% in the placebo group, with significant improvement of sleep efficiency in the nemolizumab groups. 21 At baseline, the mean weekly topical hydrocortisone butyrate use was similar between the placebo and nemolizumab groups. Notably, the use of topical hydrocortisone butyrate was significantly less in the nemolizumab groups at week 4: 9.4, 11.3, and 7.2 g/wk in the 0. Exacerbation of AD, nasopharyngitis, upper respiratory tract infections, peripheral edema, and increased creatine phosphokinase were the most common adverse events in this study. 22 Antidrug antibodies against nemolizumab were detected in three patients after nemolizumab administration, and all antibodies were confirmed as non-neutralizing. interleukins and cytokines is not affected (Figure 1) . 13 These results
indicate that IL-31 may be involved in the recruitment of polymorphonuclear cells, monocytes, and T cells to sites of skin inflammation in vivo. 13 IL-31 also increases the release of IL-6, MMP1, and MMP3 from HaCaT keratinocytes. 19, 60 Of note, the chemokine repertoires upregulated by IL-31 in keratinocytes are mostly elevated in AD as well. 13, 73 Interleukin-31 reduces the expression of skin barrier-related molecules, including desmoglein 1, desmoglein 4, desmocollin 1, desmocollin 2, corneodesmosin, caspase 14, kallikrein-like kinase 7, and filaggrin but increases the expression of antimicrobial peptides, including S100A7, S100A8, S100A9, b-defensin 2, and b-defensin 3 in the IL-31RA-expressing HaCaT keratinocytes (Figure 1 ). 74 These effects of IL-31 are likely attributed to IL-1a that is released by IL-31 stimulation because most of the IL-31-induced properties were inhibited by anakinra, a potent IL-1 receptor antagonist. 74 Loss-offunction mutations in the filaggrin gene are involved in the development of AD. 75, 76 In addition to gene mutations, the levels of filaggrin are downregulated by IL-31, 74 as well as by IL-4 and IL-13. 77 The potential proinflammatory and barrier-disrupting role of IL-31/IL-31R further stress its importance in the pathogenesis of AD.
| CONCLUSION
Pruritus and sleep disturbance are the major subjective symptom in AD and impair the patients' quality of life. 1,2,4 Among the various endogenous and exogenous prutitogens, IL-31 appears to play a critical role in atopic itch. Systemic and local administration of IL-31 induce itch and scratch in mammals including human probably in a dose-dependent manner. 19 The expression of IL-31 and its specific receptor IL-31RA is elevated not only in lesional skin but also in blood in patients with AD. 24 Subcutaneous injection of nemolizumab (anti-IL-31RA antibody) significantly inhibits the patients' itch in AD without serious adverse events. 21, 22 
